The Manufacturers Life Insurance Company Purchases 52,360 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

The Manufacturers Life Insurance Company grew its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 19.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 317,329 shares of the company's stock after purchasing an additional 52,360 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.24% of Centessa Pharmaceuticals worth $5,315,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC raised its position in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after acquiring an additional 865 shares during the last quarter. Barclays PLC raised its position in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after acquiring an additional 4,952 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Centessa Pharmaceuticals by 39.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after acquiring an additional 5,316 shares during the last quarter. XTX Topco Ltd raised its stake in shares of Centessa Pharmaceuticals by 122.9% during the fourth quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock worth $380,000 after buying an additional 12,506 shares during the last quarter. Finally, Voya Investment Management LLC bought a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth approximately $497,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Centessa Pharmaceuticals Trading Down 3.9%

NASDAQ CNTA traded down $0.51 on Tuesday, reaching $12.64. The company had a trading volume of 67,505 shares, compared to its average volume of 623,703. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The stock's 50 day moving average is $13.79 and its 200-day moving average is $15.66. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -8.26 and a beta of 1.53. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.04. Equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on CNTA. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a research note on Thursday. They set an "outperform" rating and a $6.00 price target for the company. Piper Sandler began coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an "overweight" rating and a $38.00 price target for the company. Guggenheim reissued a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Morgan Stanley reiterated an "overweight" rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, Chardan Capital started coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued a "buy" rating and a $30.00 price objective for the company. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $27.00.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total value of $163,400.00. Following the completion of the sale, the insider now directly owns 134,021 shares in the company, valued at $2,189,903.14. This represents a 6.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David M. Chao sold 7,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the sale, the insider now owns 225,007 shares of the company's stock, valued at $3,863,370.19. This trade represents a 3.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 171,398 shares of company stock worth $2,697,422 over the last ninety days. 11.59% of the stock is currently owned by corporate insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.